@ErmannMD

Lymphoma/CLL Specialist @UofUHealth @huntsmancancer | My opinions are my own |

 Salt Lake City, UT
Joined August 2018
  • Tweets121
  • Following435
  • Followers215
2Media
Had an incredible time filming and participating in this fun discussion with some amazing CLL docs. Check it out!
OncLive.com
@OncLiveFeb 12
How is the CLL treatment landscape shifting? Join experts to explore BTK and BCL2 inhibitor sequencing, MRD-guided strategies, and the role of pirtobrutinib. Watch the full series: hubs.li/Q042LWcl0 @ErmannMD @UofUHealth @huntsmancancer @JavierPinillaMD @MoffittNews @mshadman @fredhutch
147
Dr. @StevenBairMD @CULymphoma contributed to a multicenter study published in @Haematologica about real-world outcomes of lonca in R/R DLBCL. pubmed.ncbi.nlm.nih.gov/3954… #lymsm
4
11
772
Daniel A. Ermann, MD retweeted
Ajay Major, MD, MBA
@majorajay3 Mar 2025
RW lonca R/R DLBCL outcomes: - 187 pts, 17% bulky, 22% HGBL, 60% prior CAR - ORR 32%, CR 14% (woof), no diff in outcomes if prior CAR - mEFS 2.1 mos, mOS 4.6 mos Dismal outcomes outside of trial setting. #lymsm pubmed.ncbi.nlm.nih.gov/3954…
3
6
1
21
2,105
Daniel A. Ermann, MD retweeted
Ajay Major, MD, MBA
@majorajay25 Feb 2025
Mosun-pola-CHP vs pola-R-CHP 1L DLBCL - 62 pts - mosun arm: CR 73%, 2-yr PFS 71% - pola-R-CHP: CR 77%, 2-yr PFS 82% - more tx d/c in mosun arm No sig benefit of mosun-pola-CHP. #lymsm ashpublications.org/bloodadv…
6
12
3
32
4,708
Daniel A. Ermann, MD retweeted
Binaytara
@binaytara20 Feb 2025
We are excited to have @ErmannMD from @UofUHealth @huntsmancancer, @poh_christina from @fredhutch @UWMedicine and @TravisWiliamsDO from @stlukeshealth talking about #lymphoma at #BTFHemBreast25 in Boise! Join us: education.binayfoundation.or… #MedTwitter #MedX #MedEd
2
5
837
Daniel A. Ermann, MD retweeted
Ajay Major, MD, MBA
@majorajay9 Dec 2024
Pola outcomes by Hans COO @Eddie_Cliff @dgermain21 #ASH24 - >700 pts in 1L & R/R cohorts - non-GC ORR/CR significantly better in R/R (60% vs 36%), but not 1L cohort - non-GCC PFS (not OS) better in R/R, not 1L - PFS better for non-GC if pola used after (not before) CAR 1/ #lymsm
3
15
2
42
7,928
Daniel A. Ermann, MD retweeted
calliecoombs@calliecoombsmd10 Dec 2024
WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. @timfenske #ASH24
2
28
1
93
5,971
Our @CULymphoma faculty Dr. @StevenBairMD contributed to a multicenter real-world study of loncastuximab in R/R DLBCL in @Haematologica. Outcomes were inferior to those described in clinical trials, with median EFS and OS of 2.1 and 4.6 months. #lymsm pubmed.ncbi.nlm.nih.gov/3954…
1
3
13
1,021
Daniel A. Ermann, MD retweeted
Ajay Major, MD, MBA
@majorajay18 Nov 2024
Golcadomide (CELMoD)+RCHOP 1L LBCL @Lymphoma_Doc #ASH24: - randomized 0.2 vs 0.4 mg in dose expansion - 1-yr PFS 85% at 0.4 mg (77% at 0.2) - 90% EOT MRD- at 0.4 (73% at 0.2) - better EOT MRD- with 0.4 mg across high-risk genetics GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm
1
8
27
2,881
Daniel A. Ermann, MD retweeted
NEJM
@NEJM16 Oct 2024
In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS
Original Article Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma A graph of progression-free survival

ALT Original Article Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma A graph of progression-free survival

1
46
7
127
28,374
Daniel A. Ermann, MD retweeted
Binaytara
@binaytara11 Oct 2024
Congratulations to the 2024 Young Hematology Scholar Awardees! 🏆🩸Thank you for sharing your groundbreaking work and presenting at the #HemeSummit24 this weekend in Nashville! @AkritiC54828 @EmperorBlackMD @FahminB_MDPhD @LopedotePaolo @HannahGoulart @KLChohan @MDAndersonNews @MCIStrong @UICancerCenter @DukeMedSchool @COH_RadOnc @UofUHealth @NorthwesternMed Read more: binayfoundation.org/hematolo… #YoungHematologyScholars #HemOnc #Oncology #cancer #medx #meded #OncoDaily
4
7
4
31
7,183
Daniel A. Ermann, MD retweeted
Adam Kittai@AdamKittai8 Oct 2024
Interested in joining an awesome and collaborative Lymphoma team as a pharmacist? We're hiring! See attached posting. @TischCancer @IcahnMountSinai careers.accp.com/job/2155343…
2
6
408
New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer

FDA Approvals in Relapsed/Refractory CLL Set up “Difficult Choice”

In Episode 111 of Oncology Peer-Spectives, Daniel A. Ermann, MD, and Robert A. Figlin, MD, discuss how two new FDA approvals in CLL set up “a difficult choice” and what to consider when deciding.

oncologynewscentral.com
1
2
161
Daniel A. Ermann, MD retweeted
Oncology News Central@OncNewsCentral3 Aug 2024
New frontiers in r/r CLL: Dr. Daniel Ermann explores pirtobrutinib and CAR-T therapy. Key points on efficacy, toxicity, and patient selection. How will these options impact your treatment decisions? bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer
1
1
194
New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer

FDA Approvals in Relapsed/Refractory CLL Set up “Difficult Choice”

In Episode 111 of Oncology Peer-Spectives, Daniel A. Ermann, MD, and Robert A. Figlin, MD, discuss how two new FDA approvals in CLL set up “a difficult choice” and what to consider when deciding.

oncologynewscentral.com
2
1
275
Daniel A. Ermann, MD retweeted
Toby A. Eyre@tobyeyre8229 Jul 2024
Important new #CLL news PFS advantage for Acala-Ven+/-Obin vs ICT in 1L CLL. astrazeneca.com/media-centre…

Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved...

astrazeneca.com
22
2
60
11,411
Healthcare providers: Our partner, Patient Empowerment Network (PEN), is hosting a webinar addressing optimizing CLL care, with @ChangMDPhD of Emory Healthcare and @ErmannMD of Huntsman Cancer Institute, on Aug. 13 at 1pm ET. Learn more: bit.ly/3Lvy4Bo
1
2
293
Daniel A. Ermann, MD retweeted
Adam Kittai@AdamKittai3 Jul 2024
Check out @ErmannMD and my new article @ASCO, #ASCODailyNews on Treatment of Richter Transformation. @TischCancer -Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach dailynews.ascopubs.org/do/ri…

Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring...

Richter transformation is a rare complication associated with CLL for which no standard of care exists. Recent studies of combination therapies that target both the underlying CLL and the evident...

dailynews.ascopubs.org
6
12
1,086
Daniel A. Ermann, MD retweeted
Toby A. Eyre@tobyeyre8214 Mar 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma ashpublications.org/blood/ar…

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in...

Godfrey and colleagues report the first case series of patients with central nervous system (CNS) lymphoma treated with CD3-CD20 bispecific-based therapy.

ashpublications.org
34
94
7,791
Daniel A. Ermann, MD retweeted
CLL Society Inc.
@CllSociety16 Oct 2023
Data on patient outcomes for individuals with #CLL who are >80 is limited due to their underrepresentation in clinical trials. This study used information from the Mayo Clinic CLL Database to analyze how this population responds to treatment for CLL. bit.ly/46xNrSz
1
2
494
Load more